QQQ   416.98 (-1.52%)
AAPL   165.14 (-1.14%)
MSFT   399.25 (-1.24%)
META   484.04 (-3.54%)
GOOGL   153.51 (-1.60%)
AMZN   174.66 (-2.54%)
TSLA   148.73 (-0.80%)
NVDA   810.37 (-4.29%)
AMD   148.41 (-4.30%)
NIO   3.84 (-4.00%)
BABA   68.67 (-0.30%)
T   16.39 (+0.37%)
F   12.12 (+0.50%)
MU   107.68 (-3.80%)
GE   149.08 (-2.52%)
CGC   8.13 (+3.83%)
DIS   112.03 (-0.36%)
AMC   3.29 (+12.67%)
PFE   25.81 (+1.65%)
PYPL   62.14 (+0.06%)
XOM   120.16 (+1.38%)
QQQ   416.98 (-1.52%)
AAPL   165.14 (-1.14%)
MSFT   399.25 (-1.24%)
META   484.04 (-3.54%)
GOOGL   153.51 (-1.60%)
AMZN   174.66 (-2.54%)
TSLA   148.73 (-0.80%)
NVDA   810.37 (-4.29%)
AMD   148.41 (-4.30%)
NIO   3.84 (-4.00%)
BABA   68.67 (-0.30%)
T   16.39 (+0.37%)
F   12.12 (+0.50%)
MU   107.68 (-3.80%)
GE   149.08 (-2.52%)
CGC   8.13 (+3.83%)
DIS   112.03 (-0.36%)
AMC   3.29 (+12.67%)
PFE   25.81 (+1.65%)
PYPL   62.14 (+0.06%)
XOM   120.16 (+1.38%)
QQQ   416.98 (-1.52%)
AAPL   165.14 (-1.14%)
MSFT   399.25 (-1.24%)
META   484.04 (-3.54%)
GOOGL   153.51 (-1.60%)
AMZN   174.66 (-2.54%)
TSLA   148.73 (-0.80%)
NVDA   810.37 (-4.29%)
AMD   148.41 (-4.30%)
NIO   3.84 (-4.00%)
BABA   68.67 (-0.30%)
T   16.39 (+0.37%)
F   12.12 (+0.50%)
MU   107.68 (-3.80%)
GE   149.08 (-2.52%)
CGC   8.13 (+3.83%)
DIS   112.03 (-0.36%)
AMC   3.29 (+12.67%)
PFE   25.81 (+1.65%)
PYPL   62.14 (+0.06%)
XOM   120.16 (+1.38%)
QQQ   416.98 (-1.52%)
AAPL   165.14 (-1.14%)
MSFT   399.25 (-1.24%)
META   484.04 (-3.54%)
GOOGL   153.51 (-1.60%)
AMZN   174.66 (-2.54%)
TSLA   148.73 (-0.80%)
NVDA   810.37 (-4.29%)
AMD   148.41 (-4.30%)
NIO   3.84 (-4.00%)
BABA   68.67 (-0.30%)
T   16.39 (+0.37%)
F   12.12 (+0.50%)
MU   107.68 (-3.80%)
GE   149.08 (-2.52%)
CGC   8.13 (+3.83%)
DIS   112.03 (-0.36%)
AMC   3.29 (+12.67%)
PFE   25.81 (+1.65%)
PYPL   62.14 (+0.06%)
XOM   120.16 (+1.38%)
NYSE:OGEN

Oragenics (OGEN) Stock Price, News & Analysis

$1.17
+0.04 (+3.97%)
(As of 12:43 PM ET)
Today's Range
$1.16
$1.22
50-Day Range
$1.08
$6.14
52-Week Range
$1.02
$7.74
Volume
12,785 shs
Average Volume
84,059 shs
Market Capitalization
$5.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
OGEN stock logo

About Oragenics Stock (NYSE:OGEN)

Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.

OGEN Stock Price History

OGEN Stock News Headlines

Oragenics Inc
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
Oragenics Appoints Kelly As Chief Medical Officer
15 Highest Quality Probiotics For Gut Health
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
Oragenics Announces Closing of Public Offering
Oragenics announces public stock offering
Why Is Oragenics (OGEN) Stock Down 45% Today?
Oragenics Announces Pricing of Public Offering
Oragenics Shares Fall After Proposed Public Offering
Oragenics Announces Proposed Public Offering
Oragenics, Inc. Announces Leadership Transition
OGEN, RLMD and ATXI among mid-day movers
Oragenics, Inc. (UAV.F)
Oragenics Issues Update to Shareholders
See More Headlines
Receive OGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oragenics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/29/2024
Today
4/19/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Employees
5
Year Founded
N/A

Profitability

Net Income
$-20,660,000.00
Pretax Margin
-54,858.84%

Debt

Sales & Book Value

Annual Sales
$40,000.00
Book Value
$0.61 per share

Miscellaneous

Free Float
3,379,000
Market Cap
$5.15 million
Optionable
N/A
Beta
0.31
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Charles L. Pope CPA (Age 72)
    Executive Chairman
    Comp: $112.5k
  • Mr. Joseph Michael Redmond (Age 63)
    President & Interim Principal Executive Officer
  • Ms. Janet Huffman (Age 52)
    CFO, Secretary & Treasurer
    Comp: $314.9k
  • Dr. James P. Kelly M.A.
    M.D., Chief Medical Officer & Member of Scientific Advisor

OGEN Stock Analysis - Frequently Asked Questions

How have OGEN shares performed in 2024?

Oragenics' stock was trading at $6.1382 at the beginning of 2024. Since then, OGEN shares have decreased by 81.1% and is now trading at $1.16.
View the best growth stocks for 2024 here
.

How were Oragenics' earnings last quarter?

Oragenics, Inc. (NYSE:OGEN) announced its quarterly earnings results on Friday, March, 29th. The company reported ($5.48) earnings per share (EPS) for the quarter.

When did Oragenics' stock split?

Oragenics's stock reverse split on the morning of Monday, January 23rd 2023. The 1-60 reverse split was announced on Monday, January 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

What other stocks do shareholders of Oragenics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oragenics investors own include Yunji (YJ), MFA Financial (MFA) and

How do I buy shares of Oragenics?

Shares of OGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:OGEN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners